In patients with RLC > @ % ( n = @ : catumaxomab , @ and control , @ ) , catumaxomab was associated with a favorable effect on OS versus paracentesis alone ( P = @ ) , with a median/mean OS benefit of @/@ days and an increased @-month survival rate of @ % versus @ % , respectively .